Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the Stock house board. Any truth to this or rumor ??
SP IN THE 20'S WHEN THE INOVA DEAL IS ANNOUNCED
I expect and announcement within the next 7-10 business days. The bidding closed and VRX has over a billion in cash.
TAKEDA WILL COME BACK TO THE BARGAINING SOONER THAN LATER. THAT WILL BE THE CATALYST THAT WILL DRIVE THE SP INTO 30-40'S. IT WILL HAPPEN PRIOR TO Q2 EARNINGS RESULTS.
Pharmaceuticals To Present At Health Care Conferences
Valeant Pharma (NYSE:VRX)
Intraday Stock Chart
Today : Wednesday 10 May 2017
Click Here for more Valeant Pharma Charts.
LAVAL, Quebec, May 10, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the following health care conferences:
•Bank of America Merrill Lynch 2017 Healthcare Conference on Wednesday, May 17, 2017 at 3:00 p.m. PDT (6:00 p.m. EDT) at the Wynn Las Vegas hotel;
•UBS Global Healthcare Conference to be held on Monday, May 22, 2017 at 9:00 a.m. EDT at the Grand Hyatt New York hotel; and
•Jefferies 2017 Global Healthcare Conference to be held on Wednesday, June 7, 2017 at 8:30 a.m. EDT at the Grand Hyatt New York hotel.
A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: http://ir.valeant.com/events-and-presentations
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant and forward looking statements can be found at www.valeant.com.
Contact Information
Investors:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Lainie Keller
lainie.keller@valeant.com
908-927-0617
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-present-at-health-care-conferences-300455523.html
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright 2017 Canada NewsWire
If not today, maybe tomorrow.
when prices are high
they want to buy:
when prices are low
they let them go .
Ian Notely
AMEN !!!
Is more news expected short term ?
just bought more... looking good !!
Nice pullback .... filling in the Gap up.
# 0ne most active on the NYSE now !!
KA CHING !!!!
second most active stock on the NYSE now.
Thank you , good luck to you also !!!
If it pulls back I will buy more, if it goes up I'll buy more.
Thank you ! I bought 4000 yesterday under 12.
I read on VRX chat someone is expecting $20pps this week
That would be nice :)
Wow ! you are good !!!
What will the close price be on VRX today ??
Thanx.
Tismd thank you for the info !!!
I am new to this board . I have been investing in stocks for 54 years ( yes I am that old), I will never know it all.
A good trader has to have three things;
a chronic inability to accept things at face value,
to feel continuously unsettled, and have humility.
Michael Steinhart
Thanks !!!
VRX Short Interest Info.
http://shortsqueeze.com/shortinterest/stock/term2.php?s=VRX
Whats the short interest # ?
WOW Very Good news could bring $100 million in Revs!!
$12.50 great price for a stock that was 0ver $100pps at one time
PDUFA date set for December 27, 2017
LAVAL, Quebec, May 8, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesseâ„¢*), and set a PDUFA action date of December 27, 2017. Luminesse is a topical vasoconstrictor formulation to be used Over-the-Counter (OTC) as an eye drop to relieve redness of the eye due to minor eye irritations. If approved, this will be the first OTC product developed with brimonidine tartrate for the treatment of ocular redness.
"The filing acceptance of Luminesse brings us one step closer to bringing a new treatment option to potentially help patients in the more than 14 million households who use OTC eye drops to treat ocular redness," said Joseph C. Papa, Chairman and CEO of Valeant. "If approved, Luminesse may provide patients with ocular redness significant benefits versus other competing redness reliever products currently available."
Six clinical studies were conducted to evaluate the safety and effectiveness of low-dose Luminesse in relieving ocular redness, including a study to demonstrate the absence of IOP-lowering potential of low-dose brimonidine. Bausch + Lomb also conducted a comprehensive review of all post-marketing safety data, as the active ingredient brimonidine tartrate is typically found to be used in prescription ophthalmic products. The drug was found to be highly efficacious and safe with low risk of tachyphylaxis (tolerance or loss of effectiveness) and rebound congestion, which are both common to currently available OTC redness reliever eye drops.
Luminesse was licensed by Eye Therapies, Inc., to Bausch + Lomb.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.
Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates", "if approved", "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
Contact Information
Investors:
Elif McDonald
514-856-3855
877-281-6642 (toll free)
elif.mcdonald@valeant.com
Media:
Lainie Keller
Spartex sent email to u.
Sparex that's after the reverse , after an off take agreement ,after they get a mining permit etc., etc,
More "On the Come " subject to Financing Yada Yada Yada !!
Spartex ..sent again.
No, I will send again.
spartex just sent you an e-Mail ! Thanks.
spartex just sent you an e-Mail ! Thanks.
spartex send me your e-Mail via privet mail on I hub if you have it .
spartex click on the top of the ENZR hub page on the left hand side Just above the I hub postings place.
It says ENZR News: 10g
It looks like this :
ENZR News: Quarterly Report (10-q) 11/14/2016 04:04:56 PM
ENZR News: Proxy Statement (definitive) (def 14a) 11/14/2016 06:06:56 AM
ENZR News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 10/27/2016 03:40:10 PM
ENZR News: Annual Report (10-k) 09/28/2016 04:20:31 PM
ENZR News: Statement of Ownership (sc 13g)
Spartex Please go to the 8k filing item 12. 11/14 filing
Spartex ... I still didn't get answer for Bent on that question maybe you can ask Brent also. Maybe he will answer you .
I still don't see where they reported selling stock.
Spartex
Go to Item 12 on the latest 8Q ..the only insider that owns stock is Theiss.
ENZR News: Quarterly Report (10-q) 11/14/16 filing
Could they be telling great things are happening with ENZR and be blowing out stock prior to a reverse ??
Previous filings said Management owned 8% of the Company. Now they don't own any shares?????
Spartex .... Check it out for yourself... What happened to all the stock they where paid ?
ENZR Filings
SEC - CIK# 0001302084
Maybe I am missing something .... what do you think ??
TIA
spartex.. From the SEC website !
Insider Trading
"Insider trading" is a term that most investors have heard and usually associate with illegal conduct. But the term actually includes both legal and illegal conduct. The legal version is when corporate insiders—officers, directors, and employees—buy and sell stock in their own companies. When corporate insiders trade in their own securities, they must report their trades to the SEC. For more information about this type of insider trading and the reports insiders must file, please read "Forms 3, 4, 5" in our Fast Answers databank.
Illegal insider trading refers generally to buying or selling a security, in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security. Insider trading violations may also include "tipping" such information, securities trading by the person "tipped," and securities trading by those who misappropriate such information.
Examples of insider trading cases that have been brought by the SEC are cases against:
•Corporate officers, directors, and employees who traded the corporation's securities after learning of significant, confidential corporate developments;
•Friends, business associates, family members, and other "tippees" of such officers, directors, and employees, who traded the securities after receiving such information;
•Employees of law, banking, brokerage and printing firms who were given such information to provide services to the corporation whose securities they traded;
•Government employees who learned of such information because of their employment by the government; and
•Other persons who misappropriated, and took advantage of, confidential information from their employers.
Because insider trading undermines investor confidence in the fairness and integrity of the securities markets, the SEC has treated the detection and prosecution of insider trading violations as one of its enforcement priorities.
The SEC adopted new Rules 10b5-1 and 10b5-2 to resolve two insider trading issues where the courts have disagreed. Rule 10b5-1 provides that a person trades on the basis of material nonpublic information if a trader is "aware" of the material nonpublic information when making the purchase or sale. The rule also sets forth several affirmative defenses or exceptions to liability. The rule permits persons to trade in certain specified circumstances where it is clear that the information they are aware of is not a factor in the decision to trade, such as pursuant to a pre-existing plan, contract, or instruction that was made in good faith.
Rule 10b5-2 clarifies how the misappropriation theory applies to certain non-business relationships. This rule provides that a person receiving confidential information under circumstances specified in the rule would owe a duty of trust or confidence and thus could be liable under the misappropriation theory.
For more information about insider trading, please read Insider Trading—A U.S. Perspective, a speech by staff of the SEC.
spartex Hi good evening. my Previous post was the answer EGZ/ENZR Management gave me when I asked How do you own 8% of the Company when the recent filing shows the only Management shareholder is Theiss a BOD the own 70K shares.
Hey , How cam management own 8% of EGZ/ENZR when you don't own any Common Shares ??
Sent to Management
Hey Yearie , you told me there is "no insider selling" yet no insiders own stock according to the recent Filing with the exception of Thiess Jr. (70,000 shares ) ??
Please explain that to me !
Unless they have a definitive plan for someone to support the stock and or close a deal with CASH. The stock is a SCREAMING SHORT !!! There is nothing to support the higher price of the stock and it will be pounded down back to $.05 in a month !!
Im not getting paid $10,000 bucks a month for doing nothing !
We are supporting these guys with our hard earned money !
Schler and McKinnion Bailed and got about a million bucks is severance pay . IMO they have been using EGZ/ENZR as their personal piggy banks for years .
I have 500 + e-mails in my archives from Brent promising this and that for almost 7 years and never delivered one cent for shareholders or build a mine Period !!
ML Email sent to Brent.
:
To: bnykoliation <bnykoliation@energizerresources.com>; cscherba <cscherba@energizerresources.com>; qyarie <qyarie@redpineexp.com>
Sent: Thu, Sep 22, 2016 10:08 am
Subject: Re: Mistake ?
I can't believe how incompetent ENZR Management is !!!! No one proofed the The report ! To Busy counting your shares and options and outrageous salaries you get for just hiring consultants and advisors to do your work for you !!!
You all should be in Jail for scamming shareholders !!!!
Incredibly UNPROFESSIONAL all of you !!!!
The CFO didn't pick it up Shame Shame Shame !!!!!!!!!
a bunch of phony Blow Hard's !!
-----Original Message-----
From: Brent Nykoliation <bnykoliation@energizerresources.com>
Cc: Scherba Craig <cscherba@energizerresources.com>; Yarie Quentin <qyarie@redpineexp.com>
Sent: Wed, Sep 21, 2016 10:45 pm
Subject: Re: Mistake ?
Thanks - will send the author a note to correct.
Brent Nykoliation
Sr. Vice President, Corporate Development
Energizer Resources Inc.
141 Adelaide Street West, Suite 520, Toronto, ON
Tel.: +1.416.364.4911
Spartex , I don't know enough swear words to express how I feel anout this financing !!!!!!!!!!!!!!
Max hold for shares is 6 months not a year !